About Us

MBio Diagnostics® is leading a new era in rapid, on-the-spot clinical diagnostics and sample testing. We seek to be the portable platform of choice for leading providers and users of clinical and analytical testing in all market segments including: medical, veterinary, environmental, food, agriculture and military. MBio is a privately held company based in Boulder, Colorado, USA. MBio was incubated within CEO Chris Myatt’s previous company, Precision Photonics Corporation (PPC). The company was incorporated in late 2009 and spun-out as a standalone operation in early 2010, and has been funded by a dedicated, small group of private investors. MBio has also received over $20M in non-dilutive grants and contracts for programs funded by agencies including the National Institutes of Health (NIH), the National Science Foundation (NSF) and the US Department of Defense (DOD). MBio is executing on its strategy of technology partnerships and licensing to increase growth and business development opportunities.

In addition to MBio’s experienced management team, the company’s technical team consists of a select, accomplished, and integrated group of instrumentation engineers, biological assay scientists, and disposable cartridge developers. MBio’s state-of-the-art facility in Boulder includes fully equipped biosafety laboratories for biological assay development, method development and validation. The facility also includes a 3750-sq. ft. cleanroom for pilot-scale cartridge production and cartridge manufacturing process development.

Leadership

Christopher J. Myatt, Ph.D.
Chief Executive Officer

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Michael J. Lochhead, Ph.D.
Executive Vice President and Chief Technology Officer

Dr. Lochhead is a co-founder of MBio and leads technical development, collaborator activities, and intellectual property strategy. He serves as Program Manager on MBio’s commercial partnerships and is Principal Investigator on multiple major contracts with agencies including NIH, NSF and DARPA. Mike leads MBio’s talented team of instrumentation engineers and assay development scientists, and he has overall responsibility for operational scale-up of MBio’s disposable cartridge production line. Previously, Mike developed and commercialized microarray surface chemistry products at Accelr8 Technology Corporation (now Accelerate Diagnostics, Inc) where he was also part of the engineering team developing the company’s bacterial identification technology. He earned his Ph.D. in Chemical Engineering from the University of Wisconsin, Madison and completed post-doctoral training in Bioengineering at the University of Washington, Seattle. He holds B.S. and B.A. degrees from the University of Notre Dame, and is co-inventor on multiple pending and issued U.S. and international patents.

Board of Directors

Christopher J. Myatt, Ph.D.
Chief Executive Officer and Director

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Milton Chang, Ph.D.
Director

Milton Chang, Ph.D., is an angel investor mentoring and advising entrepreneurs (www.incubic.com). He is the author of Toward Entrepreneurship (www.miltonchang.com). Dr. Chang has served on many boards, and was president/CEO of Newport and New Focus, taking both companies public. He has also successfully incubated more than a dozen startup companies. Dr. Chang earned a B.S. in Electrical Engineering with highest honors from the University of Illinois and an M.S. and Ph.D. from the California Institute of Technology. He was awarded Distinguished Alumni by both universities and is a Trustee of Caltech. Dr. Chang has served on the Visiting Committee of NIST and also on an SEC advisor board.

Robert J. Silverman
Director

Robert J. Silverman is a director and strategic advisor to the company. He served as the CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer. Bob was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a $240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytyc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals. He earned his Master’s Degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. Bob received his B.S. in Pharmacy from the University of Michigan. He currently works with several companies in a Board and Advisory capacity.